Background Grass pollen is one of the most important sources of respiratory allergies
worldwide. Objective This study describes the development of a grass pollen allergy vaccine …

Allergen-specific immunotherapy is currently based on the administration of allergen
extracts containing natural allergens. However, its broad application is limited by the poor …

Background BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins
consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen …

Background We have developed a recombinant B cell epitope-based vaccine (BM32) for
allergen-specific immunotherapy (AIT) of grass pollen allergy. The vaccine contains …

Worldwide more than 200 million individuals are allergic to group 1 grass pollen allergens.
We have used the major timothy grass pollen allergen Phl p 1, which cross‐reacts with most …

Background: Pollen from different grass species are some of the most potent elicitors of Type
I allergy worldwide. The characterization of antigenic structures and IgE epitopes common to …

BACKGROUND: Allergy vaccines based on natural allergen extracts contain greatly varying
amounts of individual allergens with different immunogenicity. OBJECTIVE: To develop a …

Most of the 400 million grass pollen‐allergic patients worldwide are co‐sensitized to several
unrelated grass pollen allergens. Based on frequent co‐sensitization patterns determined in …

Background The major timothy grass pollen allergen Phl p 5 belongs to the most potent
allergens involved in hay fever and asthma. Objective This study characterized immune …

Allergen-specific immunotherapy is the only allergen-specific and disease-modifying
treatment for allergy. The construction and characterization of a vaccine for birch pollen …